Patents Examined by Lance Rider
  • Patent number: 9881707
    Abstract: The present disclosure relates to a process for synthesis of barium bismuth sulfide nanofibers, having equivalent shielding capacity as lead. The present disclosure also relates to a radiation shielding articles and cosmeceuticals.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: January 30, 2018
    Assignee: CENTRE FOR MATERIALS FOR ELECTRONICS TECHNOLOGY (C-MET)
    Inventors: Bharat B. Kale, Milind V. Kulkarni, Rajendra P. Panmand, Ujjwala V. Kawade, Sanjay K. Apte, Sonali D. Naik, Jalindar D. Ambekar, Ravindra S. Sonawane, Dinesh P. Amlanerkar, Nilofer Shroff, Sandip Chatterjee
  • Patent number: 9839607
    Abstract: The invention concerns a pH-dependent gradual sustained release composition for increasing the pH in the upper part of the small intestines. Particles of the composition are provided with a multilayer polymer coating of specific structure which ensures the gradual release of the active agent in the range of pH 4.5 to 5.5. A process for preparing said composition is also claimed.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: December 12, 2017
    Inventors: Péter Hajnal, Péter Szegó, István Nándor Antal, Judit Dredán, Imre Klebovich, Miléna Bea Lengyel
  • Patent number: 9834660
    Abstract: There is provided rare earth metal complexes of formula (I): wherein M is a cation, RE is a rare earth metal; X is a counter anion; and R1, R2, R3, and R4 are each independently selected from hydrogen, alkyl of 1-8 carbon atoms, aryl, halo, and alkoxy. Also provided is a composition of europium bis(2,2?-bipyridine-N,N?)-trinitrate with a diketonate dopant. The disclosure also provides processes for preparing the rare earth metal complexes. A mark comprising the rare earth metal complexes, and a method of applying the mark, are disclosed. The rare earth metal complexes may be used in printing systems, and for security applications.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: December 5, 2017
    Assignee: HONEYWELL INTERNATIONAL INC.
    Inventors: Thomas Potrawa, Joachim Schulz
  • Patent number: 9815958
    Abstract: Polymeric porous particles have a continuous organic solid phase and at least two sets of discrete pores that are isolated from each other within the continuous phase and that have different average sizes. One set of discrete pores has a larger average size than another set of discrete pores by at least 50%. At least one set of discrete pores is free of detectably different marker materials. There porous particles can be prepared using evaporative limited coalescence techniques with especially chosen discrete pore stabilizing hydrocolloids to protect the pores during formation and to provide the different average sizes. The resulting porous particles can be incorporated into articles of various types and having various shapes.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: November 14, 2017
    Assignee: EASTMAN KODAK COMPANY
    Inventors: David Charles Boris, Teresa Joy Hosmer, Mridula Nair
  • Patent number: 9763978
    Abstract: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: September 19, 2017
    Assignee: Valorisation-Recherche, Limited Partnership
    Inventors: Jean-Christophe Leroux, Mohamad Nasser Eddine
  • Patent number: 9750727
    Abstract: This invention relates to the field of chemical-pharmaceutical industry, specifically a new tuberculosis treatment that contains, as an active ingredient, 4-thioureido-iminomethylpyridinium perchlorate at a therapeutically effective and safe level and pharmaceutically acceptable excipients. In addition, this treatment relates to a method of the preparation of the new drug, providing a high yield of the new treatment. The new treatment has a higher tuberculostatic activity (200 times as high) and lower toxicity (2.4 times as low), as compared to a prototype drug, and is stable during long-term storage. This medicament may be used for treating and preventing all forms of pulmonary and extrapulmonary TB by using the new treatment in combination with other TB drugs.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: September 5, 2017
    Assignee: Joint Stock Company “Pharmasyntez”
    Inventors: Aleksander Sergeevich Gushchin, Tatiana Ivanovna Vinogradova, Petr Kazimirovich Yablonskiy, Gennady Andreevich Batyunin, Natalya Vyacheslavovna Zabolotnyh, Svetlana Nikolaevna Vasilieva, Alexey Vladimirovich Maligin
  • Patent number: 9718860
    Abstract: The present invention relates to a complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, to the use thereof as a drug delivery carrier for manufacturing medicines, and to a vaccine composition and a contrast agent comprising the composite. The protein comprising zinc oxide-binding peptides significantly improves the in vivo availability of zinc oxide-binding peptides, and therefore the complex of the present invention can be used not only as a drug delivery carrier for in vivo drug delivery or intracellular drug delivery, but also for in vivo imaging or cell imaging. The complex can be used for producing separating agents for effectively separating biological materials, therapeutic agents for hyperthermia, etc., contrast agents for MRI, and beads applicable to biosensors.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: August 1, 2017
    Assignees: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SNU R&DB FOUNDATION
    Inventors: Nam-Hyuk Cho, Taek-Chin Cheong, Seung-Yong Seong, Ji Hyun Min, Jun Hua Wu, Young-Keun Kim
  • Patent number: 9688856
    Abstract: The present invention relates to low-molar mass condensed derivatives of silicic acid of sub-nano particle size characterized by particular structure and specific biological activities. Preparation methods and applications are presented for the here disclosed sub-nano silicic acid (SNSA) which interact with bio-molecules and modify significantly their structure and biological function. Preferred field of application of the inventive silicic acid derivatives is to modulate the structure and biological function of proteins particularly of those involved in reversible phosphorylation within biological signal transduction or membrane transport processes. Structure of the substances, methods for the preparation and stabilization, as well as pharmaceutical compositions comprising the substances and methods of application in the prevention, diagnosis and therapy of diseases are disclosed.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: June 27, 2017
    Assignee: Sinatur GmbH
    Inventor: Franz Kerek
  • Patent number: 9687553
    Abstract: Nanocarriers are synthesized with polymers that respond to lower pH and/or ROS by being degraded. The compositions may be utilized to selectively deliver payloads within patients by responding to lower pH and/or ROS at localities within the patient. The present invention also features methods of synthesizing nanocarriers that are degraded by lower pH and/or ROS.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: June 27, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Adah Almutairi, Jagadis Sankaranarayanan, Enas Mahmoud, Eric Schopf
  • Patent number: 9682869
    Abstract: A particulate titanium dioxide has a median volume particle diameter of greater than 70 nm. The titanium dioxide can be produced by calcining precursor particles. The titanium dioxide has enhanced UVA efficacy. The particulate titanium dioxide can be used to form dispersions. The particulate titanium dioxide or dispersions can be used to produce sunscreen products having a UV protection which is at least one third of the label SPF value.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: June 20, 2017
    Assignee: Croda International PLC
    Inventors: Ian Robert Tooley, Robert Michael Sayer, Paul Martin Staniland
  • Patent number: 9682156
    Abstract: Techniques are generally described for particles with a surface including an adhesion material. The adhesion material may be selectively activated in response to radiation. The particles may be distributed proximate to a target through a fluid system. Radiation may be emitted toward the target causing the adhesion material to activate. The activated adhesive material on the surface of the particles may adhere to the target providing a fiducial mark or reference point. The fiducial mark may be visible through a medical imaging technique. In some examples, the particles may be nanoparticles. In some examples, the radiation may be infrared radiation.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: June 20, 2017
    Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventor: Ezekiel Kruglick
  • Patent number: 9675713
    Abstract: For whole animal in-situ and real-time imaging of inflammation, a dual-color fluorescent nanoprobe is provided for the detection of reactive oxygen and nitrogen species (RONS) in inflammatory microenvironments. The nanoprobes of the disclosure are a RONS-responsive energy transferring nanosystem of a fluorescent conjugated polymer core and a PEG-shell linked with RONS-sensing antennae as a FRET acceptor. These nanoprobes allow in vivo imaging of the entire process of inflammation from the release of local tissue distress signals, to the action of leukocytes and macrophages late in the process of inflammation, through to restitution, allowing in whole-body diagnosis and monitoring of inflammatory diseases.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: June 13, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jianghong Rao, Kanyi Pu, Adam Shuhendler
  • Patent number: 9675640
    Abstract: Magnetic calcium phosphate particles are provided including particles comprising iron oxide and calcium phosphate. A chitosan coating is present on the particles, wherein the particles are less than or equal to 1,000 nm, are magnetic and exhibit a positive charge in the range of 1 mVolts to 60 mVolts. The particles are provided by preparing a calcium hydroxide solution and filtering the calcium hydroxide solution in a membrane filter. An iron chloride solution is formed and combined with the filtered calcium hydroxide solution. In addition, the phosphoric acid solution is combined with the combined solutions of iron chloride and calcium hydroxide, forming a mixture including particles comprising iron oxide and calcium phosphate.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: June 13, 2017
    Assignee: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Xingguo Cheng, Qingwen Ni, Thomas B. Potter
  • Patent number: 9642803
    Abstract: Nano-sized particles are provided comprising at least one multi-headed amphiphilic compound, in which at least one headgroup of said multi-headed amphiphilic compound is selectively cleavable or contains a selectively cleavable group, and at least one biologically active agent, which is both encapsulated within the nano-particle and non-covalently associated thereto.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: May 9, 2017
    Assignee: Ben-Gurion University Of The Negev Research And Development Authority
    Inventors: Charles Linder, Sarina Grinberg, Eliahu Heldman
  • Patent number: 9629798
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: April 25, 2017
    Assignee: MALLINCKRODT PHARMA IP TRADING D.A.C.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Patent number: 9616122
    Abstract: The present invention relates to a pH sensitive particle, a method of preparation thereof, and a use thereof. More particularly, the invention provides a pH sensitive metal nanoparticle and its use for medical treatment utilizing cell necrosis during photothermal therapy. The pH sensitive metal nanoparticle based on this invention consists of a pH sensitive ligand compound whose charge changes depending on the pH of the metal nanoparticle. The particle can be collected in cells, such as cancer cells which present an abnormal pH environment. The pH sensitive metal nanoparticle based on this invention can induce cell death through a photothermal procedure after aggregation. Therefore, the invention enables medical treatment using cell necrosis for e.g. cancer treatment.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: April 11, 2017
    Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Sung Jee Kim, Sang Hwa Jeong, Hyo Kyun Chung, Ju Taek Nam, Na Youn Won
  • Patent number: 9591848
    Abstract: The present invention relates to compounds and materials that reduce the accumulation of microorganisms on a surface by interfering with the attachment of the organisms to the surface. The compounds and materials of the present invention are thus useful in preventing the formation of biofilms. The compounds of the present invention may be either adhered to a surface or integrated within a polymer. Surfaces coated by the present invention are resistant to biofilm formation, in part due to the smoothness of the surface coated with the present invention.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: March 14, 2017
    Assignee: Abilene Christian Univ.
    Inventors: T. Brian Cavitt, Rebecca Ann Herrington Faulkner
  • Patent number: 9561247
    Abstract: The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: February 7, 2017
    Assignee: TIF Management, LLC
    Inventors: Tien Nguyen, Kathleen Prudhomme, Ronald Yamamoto, Adam G. Lowe, Andrew Michael Green
  • Patent number: 9561960
    Abstract: A synthetic calcium phosphate-based biomedical material comprising gadolinium. The material may comprise a compound having the general chemical formula: Ca10?yGdy(PO4)6?x(SiO4)x(OH)2?x+y where 0<x<1.3 and 0<y<1:3.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: February 7, 2017
    Assignees: ApaTech Limited, University Court of the University of Aberdeen
    Inventors: Iain Ronald Gibson, Janet Mabel Scott Skakle, Nigel Smith, Thomas Buckland
  • Patent number: 9555134
    Abstract: Nanoparticles for use as magnetic resonance imaging contrast agents are described. The nanoparticles are made up of a polymeric support and a manganese-oxo or manganses-iron-oxo cluster having magnetic properties suitable of a contrast agent. The manganese-oxo clusters may be Mn-12 clusters, which have known characteristics of a single molecule magnet. The polymer support may form a core particle which is coated by the clusters, or the clusters may be dispersed within the polymeric agent.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: January 31, 2017
    Assignee: Georgetown University
    Inventors: Sarah Stoll, Julie Mertzman, Edward Van Keuren, Christopher Albanese, Stanley Fricke